Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | REN | P00797 | 10/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432297 | 1.00 | CTSK (0.53) | CTSKCTSSCYP3A4RENPSMB1 | |
| SCHEMBL1432294 | 1.00 | CTSK (0.53) | CTSKCTSSCYP3A4RENPSMB1 | |
| SCHEMBL1432788 | 0.90 | CTSS (0.65) | CTSKCTSSCYP3A4PSMB1PSMB8 | |
| SCHEMBL1905139 | 0.87 | CTSK (0.53) | CTSKCTSSCYP3A4RENPSMB1 | |
| SCHEMBL1905136 | 0.87 | CTSK (0.53) | CTSKCTSSCYP3A4RENPSMB1 | |
| SCHEMBL1905137 | 0.87 | CTSK (0.53) | CTSKCTSSCYP3A4RENPSMB1 | |
| SCHEMBL1431845 | 0.84 | MME (0.51) | CTSKCTSSPSMB8PSMB5MME | |
| SCHEMBL3140061 | 0.83 | CA2 (0.44) | RENCTSDCA2BACE1 | |
| SCHEMBL3140056 | 0.83 | CA2 (0.44) | RENCTSDCA2BACE1 | |
| SCHEMBL3140071 | 0.83 | CA2 (0.44) | RENCTSDCA2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CTSK 2782/4885CTSS 3171/4885CYP3A4 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.